上海源葉生物科技有限公司
主營產(chǎn)品: S30260異硫氰酸胍,30259鹽酸胍,嗜熱菌蛋白酶 |
14
聯(lián)系電話
15921386130
公司信息
- 聯(lián)系人:
- 何小姐
- 電話:
- 86-021-61559134
- 手機(jī):
- 15921386130
- 傳真:
- 86-021-55068248
- 地址:
- 上海市松江區(qū)長塔路465號(hào)6幢
- 郵編:
- 200433
- 網(wǎng)址:
- www.shyuanye.com
S80118
參考價(jià) | 面議 |
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 型號(hào)
- 品牌
- 廠商性質(zhì) 生產(chǎn)商
- 所在地
更新時(shí)間:2024-07-04 07:05:33瀏覽次數(shù):138
聯(lián)系我們時(shí)請(qǐng)說明是化工儀器網(wǎng)上看到的信息,謝謝!
- 提示:詳情請(qǐng)下載說明書。
- 產(chǎn)品描述: CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively
- 靶點(diǎn): IC50: 54 nM (rRNA synthesis, MIA PaCa-2 cells), 113 nM (rRNA synthesis, A375 cells), 142 nM (rRNA synthesis, HCT-116 cells)
- 體內(nèi)研究: CX-5461 displays antitumor activity against human solid tumors in murine xenograft models. CX-5461 (50 mg/kg, p.o.) shows significant MIA PaCa-2 growth inhibition with TGI equal to 69% on day 31 and 79% TGI on A375 on day 32. CX-5461 (50 mg/kg, p.o.) inhibits the Eμ-Myc tumor cells with 84% repression in Pol I transcription at 1 hr posttreatment in C57BL/6 mice. CX-5461 also induces a rapid reduction in tumor burden in the lymph nodes and a concomitant reduction of spleen size to within the normal range
- 參考文獻(xiàn):
1. Drygin D et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011 Feb 15;71(4):1418-30. 2. Bywater MJ, et al. Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. Cancer Cell. 2012 Jul 10;22(1):51-65.
- 溶解度: 50 mM sodium phosphate (pH 3.5) : 10 mg/mL (19.47 mM; Need ultrasonic) DMSO : < 1 mg l (ultrasonic;warming;heat to 60°c) (insoluble or slightly soluble)=""> 1 mg>
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 1.947 ml 9.735 ml 19.47 ml 5 mM 0.389 ml 1.947 ml 3.894 ml 10 mM 0.195 ml 0.974 ml 1.947 ml 50 mM 0.039 ml 0.195 ml 0.389 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的性,僅供客戶參考交流研究之用。